Combining CBD with cytostatics (e.g., etoposide) increases the therapeutic efficacy of the cytostatic drug via inhibition of the PI3K/AKT/mTOR pathway and activation of p53-dependent autophagy in NSCLC cells. Here, AKT1 is linked to non-small cell lung carcinoma.